Bone complications can result from bone metastases or cancer treatment. Skeletal-related events (SREs) including fractures, cord compression, and uncontrolled pain are a major cause of suffering and functional impairment in patients with cancer, including various solid tumors and multiple myeloma. Most patients with bone metastases will develop SREs. Bisphosphonates and denosumab have been established as effective agents to reduce skeletal morbidity, but bone-directed therapies are often underutilized. In this interactive eCourse, an expert in cancer-related bone health presents key evidence in support of bone-targeted agents in patients with cancer. In the context of patient cases, he illustrates best practices for identifying the appropriate and optimal use of bone-targeted agents and describes strategies to support patient adherence.
Interactive, audio-enhanced slide lecture
After completing this activity, participants should be better able to:
- Describe evidence supporting the use of bone-targeted agents in patients with cancer
- Identify the appropriate use of bone-targeted agents based on guidelines, clinical trial evidence, and patient factors and preferences
- Plan strategies to support patient adherence to bone-targeted therapies in cancer
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Katie Zahasky, RN, MA CNP, Oncology Nurse Practitioner, Rochester, Minnesota
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until April 7, 2023. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Amgen.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Mr Stephen: consultant/advisor/speaker: Astellas, Myovant Sciences, Pfizer.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
The estimated time to complete this activity is 1.00 hour.
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
Release date: April 8, 2022
Expiration date: April 7, 2023
© 2022 Practicing Clinicians Exchange. All Rights Reserved. PRP4641